Videos

In part 5 of the series, the clinicians explain the shift toward sulbactam-durlobactam for invasive carbapenem-resistant Acinetobacter baumannii infections and how hospitals with low CRAB volume can still plan for access.

In the fourth episode of a 6-part series, the clinicians compare agents for DTR P aeruginosa and explain why local antibiogram data should guide empiric choices.

In the third episode, the clinicians compare aztreonam-avibactam with cefiderocol for NDM-producing Enterobacterales, weigh formulary needs against local epidemiology, and discuss stewardship planning for emerging agents.

In part 2 of a 6-part series, the clinicians explain why the 2026 guidance now organizes CRE treatment by carbapenemase type and why meropenem-vaborbactam earned a slight edge for KPC producers.

This is the first in a series of discussions between medical peers on the 2026 IDSA guidance for antimicrobial-resistant gram-negative infections, beginning with current clinical challenges and new options for ESBL- and AmpC-producing organisms.

Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.

In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.

Projected disease burden from declining childhood vaccine coverage shows increases in vaccine-preventable diseases. Benjamin Lopman, PhD, provides insights on how VaxImpactMap works and the potential long-term disease consequences of decreased immunization rates.

UTI guidelines are moving away from complicated or uncomplicated infections to localized or systemic classification terminologies. Guidelines author Zachary Nelson, PharmD, MPH, BCIDP, provides further insights on the changes including applying antibiograms, potential costs, and whether clinicians will embrace these new classifications.

Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.

With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.

In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.

Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.

The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.

Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.

In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.

In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.

Gavin Harris, MD, provides some context around what is happening in the Democratic Republic of Congo regarding the outbreak including the country’s inherent challenges as well as discussing the latest in testing, vaccines, and treatments of this rare strain of Ebola.

Newly released CDC data show childhood immunization rates have steadily declined since 2020, pushing measles vaccination coverage below the threshold needed for herd immunity and leaving an estimated 280,000 kindergartners without documented vaccinations this year. Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, discusses the latest vaccine data, geographic patterns, and how public health and school officials can address this continued trend.

With the news this week that childhood vaccine exemptions were at a historical high, it is important to understand what they are and how they are applied. Pediatrician Sharon Nachman, MD, offers some insights about the ability to forgo vaccines because of exemptions.

In the second episode with Jason M. Goldman, MD, MACP, he touches upon the legal side of the order and how it may affect the childhood vaccine schedule.

In the second part of the interview with Sharon Nachman, MD, she touches upon how the administration’s shared clinical decision-making category related to childhood vaccines will affect the hepatitis B and rotavirus vaccines and the expectations there will be subsequent disease increases.

Jason M. Goldman, MD, MACP, discusses the potentially damaging effects of the rhetoric coming from the presidential executive order, including downstream consequences and his concerns about the prospective findings of the HHS Task Force on Safer Childhood Vaccines associated with the order.

The presidential executive order changing the measles, mumps and rubella (MMR) vaccine from a combination to a single-antigen vaccine means children will get more shots not less. Sharon Nachman, MD, offers some insights around the challenges of how the order’s latest changes could affect pediatric vaccine schedules.

The EU recently approved glecaprevir/pibrentasvir (Maviret), an eight-week direct-acting antiviral regimen, which offers people with hepatitis C the fastest treatment option available, giving European health systems a new tool in aiding the World Health Organization's goal of eliminating the virus by 2030.

The European Commission has approved glecaprevir/pibrentasvir (Maviret) for acute hepatitis C virus (HCV) infection, making it the only therapy approved in the European Union for both acute and chronic HCV and allowing clinicians to test and treat patients at the point of diagnosis. Mudra Kapoor, MD, discusses the phase 3 data and the treatment's potential role for greater HCV elimination.

Although there has been conflicting public information around whether the source of the outbreak has been determined, Catherine O’Neal, MD, offers insights on key symptoms that warrant medical evaluation, what medical treatment may consist of for those being seen in an outpatient setting or those who are hospitalized, and considerations around eating produce.

From the early days with no treatment, to AZT providing a lifeline, to today’s generation of antiretroviral therapies (ART), Perry N. Halkitis, PhD, MS, MPH, reminds people of how they have transformed the lives of people with HIV.